Purpose-built for cell therapy R&D
Trace every decision. From Discovery to IND / CTA Application. BioPilot replaces fragmented spreadsheets, generic ELNs, and disconnected analysis tools with one structured research engine for CAR-T, iPSC and MSC programs, connecting experiment design, inventory, bioreactor monitoring, and analytics across in vitro and in vivo work.
Seeded 2.5×10⁶ cells/well in Stage 1 media. Protocol v3.2 initiated.
Replaced 80% media with fresh Stage 1 + 100ng/mL Activin A.
~85% confluence observed. Proceeding to passage tomorrow.
Seeding density 2.0×10⁶2.5×10⁶
Reason: Protocol v3.2 amendmentELN entry signed e-signature
Protocol v3.2 locked locked
Changes need a signed reason.
The operating layer
Define stage gates, materials, sampling points and acceptance criteria. Version changes stay attributable and reviewable.
Capture observations against the correct cell source, passage, reagent lot, instrument and protocol version.
Associate FACS, imaging and omics outputs with process parameters, so teams compare runs without manual reconciliation.
iPSC. MSC. CAR-T. CAR-NK. Gene-modified. From regenerative medicine to immune cell therapy: the stages, processes, and markers you actually use, not months of custom ontology work.
Experiment design → inventory → data collection → analysis → lineage. One platform. One login. One source of truth.
Labs lose IND applications not from bad science, but from fragmented records. BioPilot builds audit trails, e-signatures, and compliance evidence during the workflow, not as a retroactive cleanup sprint before submission.
BioPilot is built for both regenerative medicine and immune cell therapy R&D: iPSC differentiation, MSC expansion, CAR-T and CAR-NK process development, and gene-modified and viral-vector workflows. Stages, media, markers and assays for these processes come pre-configured, so every run is recorded the same way and stays comparable.
Both. BioPilot combines an electronic lab notebook (ELN), a LIMS for samples, reagents, media, equipment and cell banks, a protocol builder, and built-in analysis including flow cytometry gating, scRNA-seq pipelines and Bayesian optimization. Every record is linked, from master cell bank through in vitro experiments to in vivo studies.
Benchling is a general-purpose R&D platform used across many modalities and configured to each team's workflows. BioPilot is built only for cell therapy: stage-by-day protocols, MCB/WCB cell bank genealogy, flow cytometry gating linked to CQAs and in vivo study tracking are part of the core product rather than something each team configures. If your team runs cell therapy work in Benchling today, talk to us about evaluating BioPilot alongside it.
Yes. BioPilot is built for academic and translational cell therapy labs as well as biotech and pharma R&D teams, at a price point accessible to academic groups. Versioned protocols and linked records keep work reproducible as students, postdocs and collaborators come and go, and make results easier to compare, publish and hand over.
BioPilot is built to support 21 CFR Part 11 and EU GMP Annex 11 requirements for electronic records and signatures: immutable audit trails, e-signatures bound to each record, protocol locking with version control, and end-to-end material traceability. Evidence for IND and CTA submissions is captured during the work rather than reconstructed afterwards.
BioPilot applies Bayesian optimization to your experiment history to suggest which conditions to test next, such as dissolved oxygen, temperature, agitation or compound concentration, so teams reach robust protocols in fewer runs. Scientists stay in control and review every suggestion before it is run.
BioPilot is hosted in Europe, with EU data residency by default. Your data stays yours and is never used to train external AI models.